The UK’s medicines regulator, the MHRA, approved orforglipron (brand name Foundayo) on 10 August 2026, making Britain the first in Europe to approve the GLP-1 tablet for weight management and type 2 diabetes.
The drug is approved for adults with a BMI of 30 or higher, or those with a BMI between 27 and 30 who also have at least one weight-related health condition, to be used alongside diet and exercise for weight loss and maintenance. It is also authorised to improve glycaemic control for patients with insufficiently controlled type 2 diabetes.
As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review.
About the Author: Erin Dearlove
The UK’s medicines regulator, the MHRA, approved orforglipron (brand name Foundayo) on 10 August 2026, making Britain the first in Europe to approve the GLP-1 tablet for weight management and type 2 diabetes.
The drug is approved for adults with a BMI of 30 or higher, or those with a BMI between 27 and 30 who also have at least one weight-related health condition, to be used alongside diet and exercise for weight loss and maintenance. It is also authorised to improve glycaemic control for patients with insufficiently controlled type 2 diabetes.
As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review.
About the Author: Erin Dearlove
Leave A Comment
You must be logged in to post a comment.
